Inferra AI / Company / MLAB
Mesa Laboratories Inc.
MLAB · Health Care
Last earnings Aug 10, 2026 · Next earnings Nov 9, 2026
Key results
Revenuequarter
2.4%
Revenues increased 2.4% Non-GAAP core organic revenues 1 growth was 0.4%
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Operating incomequarter
45.1%
Operating income decreased 45.1% to $3,064 primarily due to the impacts of FX and non-cash stock-based compensation expense Non-GAAP adjusted operating income ( AOI ) excluding unusual items 2 decreased 15.9% and was 21.7% as a percentage of revenues We operate our business in four divisions: Sterilization and
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Non-GAAP adjusted operating incomequarter
15.9%
Operating income decreased 45.1% to $3,064 primarily due to the impacts of FX and non-cash stock-based compensation expense Non-GAAP adjusted operating income ( AOI ) excluding unusual items 2 decreased 15.9% and was 21.7% as a percentage of revenues We operate our business in four divisions: Sterilization and
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Executive Commentary (amounts in thousands) Against a highly volatile macroeconomic environment, the team s leverage of the Mesa Way operating model delivered quarterly revenues of $59,543 or 2.4% organic (0.4% core organic) revenues growth.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
CG China revenuequarter
7.9%
Strong growth in SDC and CG growth of 7.9% excluding China overcame a continued contraction of CG China revenues of approximately $1.8M or 69% as compared to the same quarter in the prior year.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Operating income decreased 45.1% to $3,064.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Net incomequarter
$4,742,
Net income was $4,742, an increase of 40.0%, or $0.85 per diluted share of common stock.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
On a non-GAAP basis, core organic revenues growth was 0.4% and AOI decreased 7.7% to $12,902 or $2.32 per diluted share of common stock, compared to 1Q25.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
revenues were $25,410 for the quarter, which delivered core organic revenues growth of 7.5%.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
AI analysis
Q1 2026 · reported Aug 5, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q1 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | 2.4% | — | — |
| Operating income | 45.1% | — | — |
| Non-GAAP adjusted operating income | 15.9% | — | — |
| CG China revenue | 7.9% | — | — |
| Net income | $4,742, | — | — |
Guidance · company-stated
No guidance located in the held release
Capital allocation
3 Total Net Leverage Ratio under our Credit Facility is defined as the ratio of total debt minus unrestricted cash in excess of $10 million as compared to 12 months trailing EBITDA.
Fair Value Measurements and Concentrations of Credit Risk Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt.
Company-stated claims
Historical · increased 129% · income
“Operating income increased 129% to $7,031.”
EX-99 · Aug 10, 2026Event summary
Mesa Labs Announces First Quarter Results Lakewood, Colorado , August 5, 2025 Mesa
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
3 Total Net Leverage Ratio under our Credit Facility is defined as the ratio of total debt minus unrestricted cash in excess of $10 million as compared to 12 months trailing EBITDA.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Fair Value Measurements and Concentrations of Credit Risk Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt.
SEC original ↗Mesa Laboratories Inc. — 10-Q Quarterly report10-QAug 10, 2026
The carrying amounts of our term loan and revolving line of credit (together, the "Credit Facility") approximate fair value due to variable interest rate pricing, with the balances bearing interest rates approximating current market rates.
SEC original ↗Mesa Laboratories Inc. — 10-Q Quarterly report10-QAug 10, 2026
Indebtedness Credit Facility Our secured credit agreement matures in April 2029 and includes: (i) A revolving credit facility with an aggregate principal amount of up to $ 125,000 (the "Revolver"), (ii) A term loan with a maximum principal amount of $ 75,000 , which is subject to escalating quarterly principal payments (the "Term Loan"), (iii) A swingline loan with an aggregate principal amount not exceeding $ 5,000 , and (iv) Letters of credit with an aggregate stated amount not exceeding $ 2,500 at any time.
SEC original ↗Mesa Laboratories Inc. — 10-Q Quarterly report10-QAug 10, 2026
Borrowings under our Credit Facility bear interest at a Secured Overnight Financing Rate ("SOFR") rate or a base rate, plus an applicable spread that varies with our total net leverage ratio.
SEC original ↗Mesa Laboratories Inc. — 10-Q Quarterly report10-QAug 10, 2026
The weighted average interest rate on borrowings under the Credit Facility was 5.6 % as of June 30, 2026 and 5.9 % as of March 31, 2026.
SEC original ↗Mesa Laboratories Inc. — 10-Q Quarterly report10-QAug 10, 2026
Strategy & priorities
The remaining contraction was primarily due to FX and the impact of strategically prioritized BPD shipments of low margin hardware to China.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
We will continue to work diligently to counter the impact of tariffs on the bottom line through a combination of price increases or surcharges while prioritizing customer retention and topline growth.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
The Mesa Way was in action this May in Breakthrough 7, where we began deploying this year s Clinical Genomics division s strategic plan.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
In Breakthrough 7 we focused on accelerating New Product Development, excellence in Product Launches, spreading best practices and tools for Customer Prospecting, and Manufacturing Scrap Reduction.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
While 1Q26 was challenging in the face of a difficult macroeconomic environment, we are encouraged by our continuing commercial success, traction with key initiatives, and the resilience of our operating model concluded Mr.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Risks & headwinds
Negotiating final tariff surcharges in BPD resulted in approximately $1.5M of expected 1Q26 revenues shifting into 2Q26.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Gross profit percentage contracted by 200 bps versus the first quarter of the prior year (which included $778 of non-cash inventory step up amortization), of which 40 bps were associated with tariff-related charges.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
In total we paid approximately 1% of revenues in tariffs with a significant portion either passed onto customers or capitalized into inventory.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
We will continue to work diligently to counter the impact of tariffs on the bottom line through a combination of price increases or surcharges while prioritizing customer retention and topline growth.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Gross profit percentage decreased by 440 bps for the quarter, primarily due to raw material price headwinds driven by tariffs, increased labor costs, and to a lesser extent product mix.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
The China contraction was driven by macroeconomic and tariff uncertainty as well as ongoing regulatory headwinds.
SEC original ↗Mesa Laboratories Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
32 documents- Q3 2026
- 8-KMLAB
Oct 13, 2026
- EX-99MLAB
Oct 13, 2026
- Q2 2026
- 8-KMLAB
Sep 8, 2026
- 8-KMLAB
Aug 10, 2026
- 10-QMLAB
Aug 10, 2026
- 8-KMLAB
Jul 30, 2026
- Q1 2026
- 8-KMLAB
Jun 15, 2026
- 10-KMLAB
Jun 3, 2026
- 8-KMLAB
May 27, 2026
- Q4 2025
- 8-KMLAB
Mar 23, 2026
- 8-KMLAB
Mar 9, 2026
- EX-99MLAB
- 8-KMLAB
Feb 3, 2026
- 10-QMLAB
- Q3 2025
- 8-KMLAB
Nov 6, 2025
- 10-QMLAB
- Q2 2025
- 8-KMLAB
Aug 25, 2025
- 8-KMLAB
Aug 18, 2025
- 8-KMLAB
Aug 5, 2025
- 10-QMLAB
- Q1 2025
- 8-KMLAB
Jun 6, 2025
- 8-KMLAB
May 28, 2025
- 10-KMLAB
May 28, 2025
- Q4 2024
- 8-KMLAB
Feb 4, 2025
- 10-QMLAB
- Q3 2024
- 8-KMLAB
Nov 7, 2024
- 10-QMLAB
- Q2 2024
- 8-KMLAB
Sep 11, 2024
- 8-KMLAB
Aug 30, 2024
- 8-KMLAB
Aug 5, 2024
- 10-QMLAB
- Q1 2024
- 10-KMLAB
Jun 28, 2024
Earnings releases
10 documentsPresentations
0 documentsNo presentations for Mesa Laboratories Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Mesa Laboratories Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.